Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System cut its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCIFree Report) by 4.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 92,450 shares of the biopharmaceutical company’s stock after selling 4,571 shares during the period. California State Teachers Retirement System owned approximately 0.10% of Intra-Cellular Therapies worth $6,621,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ITCI. Signaturefd LLC lifted its position in Intra-Cellular Therapies by 85.7% during the fourth quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 239 shares in the last quarter. Neo Ivy Capital Management acquired a new position in Intra-Cellular Therapies during the third quarter valued at approximately $45,000. Cape Investment Advisory Inc. acquired a new position in Intra-Cellular Therapies during the fourth quarter valued at approximately $78,000. CI Investments Inc. lifted its position in Intra-Cellular Therapies by 1,191.6% during the third quarter. CI Investments Inc. now owns 1,692 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 1,561 shares in the last quarter. Finally, Parallel Advisors LLC lifted its position in Intra-Cellular Therapies by 16.3% during the fourth quarter. Parallel Advisors LLC now owns 1,564 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 219 shares in the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

Intra-Cellular Therapies Trading Up 1.0 %

Shares of NASDAQ:ITCI opened at $69.07 on Tuesday. The company has a fifty day simple moving average of $68.76 and a 200 day simple moving average of $68.06. The firm has a market cap of $7.29 billion, a PE ratio of -59.54 and a beta of 0.98. Intra-Cellular Therapies, Inc. has a 12-month low of $45.50 and a 12-month high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCIGet Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. The business had revenue of $144.90 million during the quarter, compared to analyst estimates of $141.41 million. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. The business’s revenue was up 52.0% compared to the same quarter last year. As a group, equities research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.53 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on ITCI shares. Canaccord Genuity Group lifted their price target on shares of Intra-Cellular Therapies from $100.00 to $107.00 and gave the company a “buy” rating in a research report on Tuesday, April 23rd. The Goldman Sachs Group lifted their price target on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a research report on Wednesday, April 17th. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Intra-Cellular Therapies in a research report on Tuesday, May 7th. Royal Bank of Canada reissued an “outperform” rating and set a $86.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, April 3rd. Finally, Bank of America boosted their target price on shares of Intra-Cellular Therapies from $82.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $92.73.

Read Our Latest Research Report on ITCI

Intra-Cellular Therapies Company Profile

(Free Report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

Further Reading

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.